Alvotech Expands its 2018 Collaboration with Fuji Pharma to Develop and commercialize Biosimilar Therapies in Japan
Shots:
- Alvotech to receive upfront and is eligible to receive milestones for the development progression, along with share in-market sales
- Fuji to get exclusive rights to an undisclosed biosimilar which is currently in the early phase of development. The new agreement adds another biosimilar candidate under the 2018 collaboration b/w Alvotech and Fuji
- On Dec 7, 2021, Alvotech had entered into a definitive business combination agreement with Oaktree & the combined company’s securities are expected to be listed on NASDAQ under the symbol “ALVO”, following the completion of the transaction
Ref: Businesswire | Image: Alvotech
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
